A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer
Study Information
Alliance Study ID: AFT-31
NCT Study ID (ClinicalTrials.gov): NCT02967133
Alliance Committee: Respiratory Cancer
Disease or Cancer Type: Lung Cancer & Mesothelioma
Alliance Study Chair: Neal Ready, MD, PhD
Status: TERMINATED
Study Description
The optimal prioritization of second-line chemotherapy and immune therapy based on demographic or biomarker data is an area of ongoing investigation. The hypothesis of this study is that there may be an additive or synergistic antitumor effect of combined chemotherapy and nivolumab in the second-line treatment of NSCLC as an important concept to test in a clinical trial. Previously treated NSCLC remains a setting of unmet clinical need despite recent clinical research progress. Early progression for a subset of NSCLC patients receiving nivolumab is a specific area of clinical need.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Data Sources & Contacts
Full trial details
For more Information